Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efbalropendekin alfa - Genentech/Xencor

Next Previous
Drug Profile

Efbalropendekin alfa - Genentech/Xencor

Alternative Names: IL15/IL15Ra-Fc; RG-6323; RO-7310729; XmAb 306; XmAB24306; XmAb®24306

Latest Information Update: 26 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Xencor
  • Developer Genentech; Xencor
  • Class Antineoplastics; Bispecific antibodies; Immunoglobulin Fc fragments; Immunotherapies; Interleukins; Recombinant fusion proteins
  • Mechanism of Action Interleukin-2 receptor beta subunit agonists; Natural killer cell stimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Multiple myeloma; Solid tumours

Most Recent Events

  • 26 Feb 2025 Discontinued - Phase-I for Multiple myeloma (Combination therapy, Late-stage disease, Second-line therapy or greater) in Australia, Denmark, Norway, Spain (IV) (Roche pipeline, February 2025)
  • 26 Feb 2025 Discontinued - Phase-I for Multiple myeloma (Combination therapy, Second-line therapy or greater) in Greece, Australia, Israel, South Korea, Norway, Spain, Denmark (IV) (Roche pipeline, February 2025)
  • 26 Feb 2025 Discontinued - Phase-I for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Recurrent) in USA, Australia, Italy, South Korea, Netherlands, Canada, Belgium, Brazil, Spain (IV) (Roche pipeline, February 2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top